S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
How Biden has already won 2024 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The #1 Crypto for 2024 (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
How Biden has already won 2024 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The #1 Crypto for 2024 (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
How Biden has already won 2024 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The #1 Crypto for 2024 (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
How Biden has already won 2024 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The #1 Crypto for 2024 (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
ASX:BGT

Bio-Gene Technology (BGT) Stock Price, News & Analysis

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)
Free BGT Stock Alerts
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
BGT stock logo

About Bio-Gene Technology Stock (ASX:BGT)

Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. Its lead products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural oil extracted from a cultivar of eucalyptus cloeziana. The company has a research collaboration agreement with James Cook University to refine the process for oil extraction; and with BASF, Grains Research and Development Corporation, and Queensland Department of Agriculture and Fisheries for testing of Flavocide in grain storage. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.

BGT Stock News Headlines

April 15, 2024 | msn.com
Bio-Rad announces collaboration agreement with oncocyte to commercialize transplant monitoring with droplet digital PCR
March 20, 2024 | msn.com
Biotech with links to Boston sets record price for new gene therapy for rare childhood disease
April 19, 2024 | Crypto Swap Profits (Ad)
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
March 4, 2024 | forbes.com
Science Continues To Outpace Commercialization Of Cell And Gene Therapies
January 23, 2024 | wsj.com
Bio-Gene Technology Ltd.
December 13, 2023 | msn.com
3 Biotechs With Promising Gene Therapies in the Spotlight
December 11, 2023 | bizjournals.com
University of Pennsylvania Gene Therapy Program cuts staff by 25%, report says
December 4, 2023 | bizjournals.com
Durham biotech seeks partner to advance its gene therapy
April 19, 2024 | Crypto Swap Profits (Ad)
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
November 30, 2023 | msn.com
Generation bio cuts 40% of staff in blow for non-viral gene therapy sector
November 28, 2023 | markets.businessinsider.com
Gene Bio Medical (GBM): Leading the Charge in Biotechnological Innovation and Global Healthcare Revolution
November 8, 2023 | businesswire.com
bit.bio Unveils Cell Therapy Pipeline, Including Lead Candidate for Acute Liver Failure, and Significantly Expands Scientific Advisory Board with Global Experts in Cell Therapy
November 8, 2023 | msn.com
Cell and gene therapy biotechs face access hurdles in Europe
November 6, 2023 | tmcnet.com
Genevant Sciences to Collaborate with Novo Nordisk to Develop Gene Editing Treatment for Hemophilia A
September 25, 2023 | msn.com
Are Gene Therapy Stocks The Market's Next Big Winners?
September 20, 2023 | msn.com
Pelican and Primordial Genetics merge to form biotech company Primrose Bio
September 18, 2023 | markets.businessinsider.com
Biosyngen received the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2023
August 28, 2023 | markets.businessinsider.com
Life Science Firm Bio-Techne's Success Formula: Astute Acquisitions Offering Transformation
August 15, 2023 | msn.com
BTIG Maintains Mustang Bio (MBIO) Buy Recommendation
August 11, 2023 | wsj.com
Senior Personal Technology Columnist, The Wall Street Journal
August 1, 2023 | bizjournals.com
Gene therapy startup founded by Pfizer, Biogen vet to shut down
June 5, 2023 | finance.yahoo.com
Form Bio Announces FORMsightAI, a Breakthrough AI Solution Set for Predicting and Optimizing Cell & Gene Therapy Manufacturability
May 24, 2023 | bizjournals.com
In another mega-round, ElevateBio raises $401M for cell and gene therapy
May 19, 2023 | benzinga.com
Scout Bio to Present at Upcoming Gene and Cell Therapy Summit
May 10, 2023 | businesswire.com
Life Biosciences and Forge Biologics Announce cGMP Manufacturing Partnership to Advance Development of Novel Gene Therapies for Aging-Related Diseases
May 4, 2023 | marketwatch.com
Mekonos Announces Research Collaboration With bit.bio to Advance Cell Engineering
May 2, 2023 | marketwatch.com
Gene Engineered Subunit Vaccine Market Size 2023-2031 Industrial Regions by Absolute Reports | with [85 Pages]
See More Headlines
Receive BGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Gene Technology and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:BGT
CUSIP
N/A
CIK
N/A
Web
www.bio-gene.com.au
Phone
61 3 9628 4178
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
A($0.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-2,630,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-65.75%
Return on Assets
-35.65%

Debt

Debt-to-Equity Ratio
0.11
Current Ratio
7.08
Quick Ratio
6.72

Sales & Book Value

Annual Sales
$445,726.00
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
7.04
Book Value
A$0.02 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
201,360,000
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.35
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Roger McPherson B.Bus
    C.P.A., CPA, GAICD, Interim CFO & Company Secretary
  • Mr. Peter Donald May AFA1M
    AFAIM, GAICD, M.B.A., MBA, Executive Director of Research & Development and Executive Director
  • Mr. Timothy Owen Grogan B.Sc.
    LLB, MD, CEO & Director

Key Competitors

View All Competitors

Insiders


This page (ASX:BGT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
How Biden has already won 2024
Porter & Company
Man Who Predicted 2008: “This Will be Worse.”
Altimetry
Options trading has suddenly become more reliable.
Eagle Publishing